Comparative modes of chromatin engagement by PAX::FOXO1 fusions in rhabdomyosarcoma
Alexi M TallaniD, Jack P. KucinskiiD, Andrew M. VontelliD, Chamithi KarunanayakeiD, Rachel A. HoffmaniD, Benjamin D. SunkeliD, Cenny TaslimiD, Genevieve C. KendalliD, Benjamin Z. StantoniD
Abstract
Fusion positive rhabdomyosarcoma (FP-RMS) is an aggressive soft-tissue sarcoma that most frequently affects children and adolescents. Treatment options and outcomes for children with this cancer remain poor, non-specific, and broadly toxic despite decades of research. The defining molecular drivers of the more aggressive fusion-positive subtype of the disease arise from chromosomal translocations that fuse PAX3 or PAX7 to FOXO1 to form PAX3::FOXO1 or PAX7::FOXO1, encoding fusion oncoprotein transcription factors. Despite their high degree of similarity, PAX3::FOXO1 correlates with worse patient overall survival than PAX7::FOXO1. Previous work from our groups and others has revealed evidence focused in chromatin accessibility contexts that PAX3::FOXO1 has key characteristics of a pioneer transcription factor, a specialized subclass of transcription factors that can bind nucleosomal DNA prior to generation of local accessibility. However, evidence at the genome scale for PAX3/7::FOXO1 direct nucleosome targeting, prior to the accessibility step in pioneering, has remained elusive and challenging to capture methodologically for RMS fusion oncoproteins. In this work, we compare the cellular functions of these PAX::FOXO1 fusions, including new approaches for identifying nucleosome targeting at the genome scale. We find that in zebrafish RMS initiation models, the fusions initially activate similar neural transcriptional programs but to different extents, and we further evaluate their mechanisms in RMS cells at the genome scale with modified MNase XChIP to detect nucleosome and subnucleosome fusion/chromatin binding. In establishing our cross-species comparative oncology approach, we report, to our knowledge, the first high resolution nucleosome positioning data in rhabdomyosarcoma. We find that both PAX::FOXO1 fusions bind nucleosomal DNA, but with varied motif preferences and histone mark co-localization patterns. Altogether, we establish the nucleosome targeting functions of PAX7::FOXO1 and PAX3::FOXO1 pioneering and uncover key mechanistic distinctions for chromatin engagement of the two most common RMS fusion oncoproteins. HIGHLIGHTSO_LIPartially overlapping gene signatures are activated by PAX3/7::FOXO1 in vivo C_LIO_LIModified MNase ChIP reveals PAX3/7::FOXO1 bind nucleosomal and subnucleosomal DNA C_LIO_LIPAX7::FOXO1 binds degenerate paired/homeobox motifs within nucleosome targets C_LIO_LIEach fusion engages distinct nucleosomal gene targets C_LI
02 /Specification & Classification
Click any tag to browse matching papers- Citations
- 1
- Organism
- Assay
- Research Focus
- Approach
Reproducibility ledger
Nobody has reported trying to reproduce this paper yet. Did you replicate an experiment or run the code? Your report saves the next lab a week.
Sign in to file a reproducibility report.
Related papers
- Rhabdomyosarcoma fusion oncoprotein initially pioneers a neural signature in vivo
Jack P. Kucinski, Alexi M Tallan, … Genevieve C. Kendall·Cell ReportsPeer-reviewed·Jul 1, 2025
- Fusion transcription factor dosage controls cell state in rhabdomyosarcoma
Rachel A. Hoffman, Meng Wang, … Benjamin Z. Stanton·bioRxiv·May 16, 2025
- RUNX2 inhibition disrupts a PAX3::FOXO1-RUNX2 feed-forward loop and dismantles oncogenic gene programs in fusion-positive rhabdomyosarcoma
Elizabeth A. Mendes, Aanandi Munshi, … Corinne Mary Linardic·bioRxiv·Jul 21, 2025
- Pioneer activity of an oncogenic fusion transcription factor at inaccessible chromatin
Benjamin D. Sunkel, Meng Wang, … Benjamin Z. Stanton·iSciencePeer-reviewed·Jul 16, 2021
- USP7 sustains PAX3::FOXO1 enhancer reprogramming and represents a therapeutic vulnerability in Rhabdomyosarcoma
Pablo Táboas, Enrique Blanco, … Sara Sánchez-Molina·bioRxiv·Jun 8, 2026
- Divergent transcriptional and transforming properties of PAX3-FOXO1 and PAX7-FOXO1 paralogs
L. MANCEAU, J. RICHARD ALBERT, … V. Ribes·bioRxiv·Aug 18, 2021